Therapeutic HDAC inhibition in hypermutant diffuse intrinsic pontine glioma
Open Access
Abstract
No abstract availableKeywords
Funding Information
- Andrew McDonough B+ Foundation
- McKenna Claire Foundation
- National Institutes of Health (R01CA114567)
- American Association for Cancer Research
- Entertainment Industry Foundation
This publication has 51 references indexed in Scilit:
- Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade gliomaNature Reviews Cancer, 2014
- The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade gliomaNature Genetics, 2014
- Recurrent activating ACVR1 mutations in diffuse intrinsic pontine gliomaNature Genetics, 2014
- K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomasActa Neuropathologica, 2012
- Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastomaNature, 2012
- Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomasNature Genetics, 2012
- Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology GroupNeuro-Oncology, 2011
- Loss of the Mismatch Repair Protein MSH6 in Human Glioblastomas Is Associated with Tumor Progression during Temozolomide TreatmentClinical Cancer Research, 2007
- A Hypermutation Phenotype and Somatic MSH6 Mutations in Recurrent Human Malignant Gliomas after Alkylator ChemotherapyCancer Research, 2006
- Histone Acetylation-independent Effect of Histone Deacetylase Inhibitors on Akt through the Reshuffling of Protein Phosphatase 1 ComplexesJournal of Biological Chemistry, 2005